← All Lexeo Therapeutics, INC filings

Lexeo Therapeutics, INC 8-K filings

NASDAQ
LXEO
Lexeo Therapeutics, INC
8-K: Lexeo Therapeutics Licenses Gene Therapy Data from Cornell to Advance Friedreich Ataxia Treatment
Lexeo Therapeutics has secured an exclusive license from Cornell University for gene therapy data related to Friedreich's ataxia cardiomyopathy, aiming to accelerate the development of their drug candidate LX2006.
NASDAQ
LXEO
Lexeo Therapeutics, INC
8-K: Lexeo Therapeutics Director to Step Down at 2024 Annual Meeting
Lexeo Therapeutics announces that director Bernard Davitian will not seek re-election at the company's 2024 annual meeting.
NASDAQ
LXEO
Lexeo Therapeutics, INC
8-K: Lexeo Therapeutics Receives FDA Fast Track Designation for Gene Therapy LX2006
Lexeo Therapeutics has been granted Fast Track designation by the FDA for its gene therapy candidate, LX2006, aimed at treating Friedreich's ataxia cardiomyopathy.
NASDAQ
LXEO
Lexeo Therapeutics, INC
8-K: Lexeo Therapeutics Secures $95 Million in Private Placement, Extends Cash Runway into 2027
Lexeo Therapeutics has announced a $95 million private placement to fund operations into 2027, alongside positive clinical trial updates and 2023 financial results.
NASDAQ
LXEO
Lexeo Therapeutics, INC
8-K: Lexeo Therapeutics Bolsters Leadership Team with Key Executive Appointments
Lexeo Therapeutics has announced the appointment of several new executives to lead the company's pipeline into late-stage clinical development.